Role of Gastroinestinal Endoscopy in Pediatric Failure to Thrive

NCT07160387 | Not Yet Recruiting DMC

• 1 other identifier: GIT endoscopy in children FTT
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to evaluate the diagnostic role of gastrointestinal endoscopy in children presenting with failure to thrive and its correlation with histopathology and other diagnostic modalities.

Conditions

Failure to Thrive; Endoscope

Outcome Measures

Primary Outcomes (1)

• Role of Gastrointestinal Endoscopy in Evaluation of Pediatric Failure to Thrive

  evaluate the diagnostic role of gastrointestinal endoscopy in children presenting with failure to thrive and its correlation with histopathology and other diagnostic modalities.

  baseline

Eligibility Criteria

• Age: 6 Months - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

any child from6 months to 18 years and has unexplained failure to thrive failure to thrive means: Weight-for-age below the 5th percentile for sex/age or crossing downward by ≥2 major percentiles lines on a standardized growth chart confirmed on two measurements.

You may qualify if:

• Age from 6 months to 18 years..
• Both sexes.
• Diagnosed with failure to thrive, defined as :
• Weight-for-age below the 5th percentile for sex/age or crossing downward by ≥2 major percentiles, confirmed on two measurements.
• Clinical suspicion of an underlying gastrointestinal cause (e.g., chronic vomiting, chronic diarrhea either bloody or not, chronic abdominal pain and/or gastrointestinal bleeding
• Parental/guardian consent for their siblings to share in the study

You may not qualify if:

• Known chronic disease already causing failure to thrive (genetic, cardiac, renal, or endocrine disorders).
• Contraindications to endoscopy or anesthesia (e.g. severe coagulopathy, unstable cardiopulmonary status).
• Parental refusal to participate or consent for endoscopy

Sponsors & Collaborators

• Assiut University: lead

Related Publications (8)

• Burayzat S, Odeh M, Altamimi E, Al-Dweik S, El Wahab K, Alanasweh M, Al-Khraisat M, Barqawi M. Eesophagogastroduodenoscopy in paediatrics: does abiding by the international guidelines lead to appropriate management? A cross-sectional study. BMJ Open. 2022 Sep 1;12(9):e061489. doi: 10.1136/bmjopen-2022-061489.

  PMID: 36581988 BACKGROUND

• Ngo PD, Lightdale JR. Advances in Pediatric Endoscopy. Gastroenterol Clin North Am. 2024 Dec;53(4):539-555. doi: 10.1016/j.gtc.2024.08.010. Epub 2024 Sep 30.

  PMID: 39489574 BACKGROUND

• Sidhu R, Turnbull D, Haboubi H, Leeds JS, Healey C, Hebbar S, Collins P, Jones W, Peerally MF, Brogden S, Neilson LJ, Nayar M, Gath J, Foulkes G, Trudgill NJ, Penman I. British Society of Gastroenterology guidelines on sedation in gastrointestinal endoscopy. Gut. 2024 Jan 5;73(2):219-245. doi: 10.1136/gutjnl-2023-330396.

  PMID: 37816587 BACKGROUND

• Lawson NR, Angelo J, Chiou E, Glinton K, Dean A. Failure to Thrive, Metabolic Acidosis, and Diarrhea in a 7-Week-Old Infant. Pediatrics. 2024 Sep 1;154(3):e2023064240. doi: 10.1542/peds.2023-064240.

  PMID: 39086356 BACKGROUND

• Amil-Dias J, Oliva S, Papadopoulou A, Thomson M, Gutierrez-Junquera C, Kalach N, Orel R, Auth MK, Nijenhuis-Hendriks D, Strisciuglio C, Bauraind O, Chong S, Ortega GD, Fernandez SF, Furman M, Garcia-Puig R, Gottrand F, Homan M, Huysentruyt K, Kostovski A, Otte S, Rea F, Roma E, Romano C, Tzivinikos C, Urbonas V, Velde SV, Zangen T, Zevit N. Diagnosis and management of eosinophilic esophagitis in children: An update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2024 Aug;79(2):394-437. doi: 10.1002/jpn3.12188. Epub 2024 Jun 24.

  PMID: 38923067 BACKGROUND

• McDonald CM, Reid EK, Pohl JF, Yuzyuk TK, Padula LM, Vavrina K, Altman K. Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy. Nutr Clin Pract. 2024 Apr;39 Suppl 1:S57-S77. doi: 10.1002/ncp.11122.

  PMID: 38429959 BACKGROUND

• Smith AE, Shah M, Badireddy M. Failure to Thrive. 2023 Nov 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK459287/

  PMID: 29083644 BACKGROUND

• Lin YC, Yen HR, Tsai FJ, Wang CH, Chien LC, Chen AC, Lin RT. Effects of cyproheptadine on body weight gain in children with nonorganic failure to thrive in Taiwan: A hospital-based retrospective study. PLoS One. 2021 Oct 19;16(10):e0258731. doi: 10.1371/journal.pone.0258731. eCollection 2021.

  PMID: 34665812 BACKGROUND

Related Links

• Endoscopic biopsies - The gastrointestinal undercover agent!
• Weight-Faltering in Infants and Children (Failure to Thrive)

MeSH Terms

Conditions

Failure to Thrive

Condition Hierarchy (Ancestors)

Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Mohamed Ahmed Abdelrady, resident pediatric

CONTACT

+201097225957; drrady2022@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: resident pediatric

Study Record Dates

• First Submitted: August 29, 2025
• First Posted: September 8, 2025
• Study Start: September 20, 2025
• Primary Completion (Estimated): March 20, 2027
• Study Completion (Estimated): April 20, 2027
• Last Updated: September 8, 2025

Record last verified: 2025-08